-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Secures Winning Bids for Three Products Across Five Specifications in Inter-Provincial Consortium Centralized Procurement
Category:
发布时间：2026-01-30
【概要描述】
On January 29, the Hebei Provincial Centralized Procurement Center for Medical Drugs and Devices issued the “Notice on Announcing the Winning Results of the Renewed Centralized Procurement of Drugs under the Hebei Provincial Alliance (Provincial) Procurement Initiative.” In this round of renewed centralized procurement for drugs expiring under the Hebei Provincial Alliance initiative, as well as in the earlier Beijing–Tianjin–Hebei–Jiangxi centralized volume-based procurement of chemical pharmaceuticals led by Hebei, Shijiazhuang Sihua Pharmaceutical Group successfully secured winning bids for a total of three drug varieties across five dosage forms. This achievement fully underscores the company’s strong brand influence and market competitiveness.
On January 29, the Hebei Provincial Centralized Procurement Center for Medical Drugs and Devices issued the “Notice on Announcing the Winning Bids in the Renewal Centralized Procurement of Expired Drugs under the Hebei Provincial Alliance (Provincial) Centralized Procurement.” In this round of renewal centralized procurement for drugs whose previous contracts have expired, as well as in the earlier Beijing–Tianjin–Hebei–Jiangxi centralized volume-based procurement of chemical drugs led by Hebei Province, Shijiazhuang Sihua Pharmaceutical Group successfully secured winning bids for a total of three drug varieties across five dosage forms. This achievement fully demonstrates the company’s strong brand influence and market competitiveness.
In the renewal phase of the Hebei Provincial Alliance centralized procurement program, Shijiazhuang Sihua Pharmaceutical’s Ondansetron Hydrochloride Tablets (4 mg and 8 mg) were selected with a clear advantage. This medication is indicated for the treatment and prevention of nausea and vomiting associated with radiotherapy, chemotherapy, and postoperative recovery, with a contracted procurement volume of nearly 2 million tablets in the first year, thereby providing patients with cost-effective clinical treatment assurance.
Meanwhile, in the volume-based procurement of chemical pharmaceuticals for the Beijing–Tianjin–Hebei–Jiangxi region led by Hebei Province, two specifications of cefuroxime axetil dry suspension—0.25 g based on C16H16N4O8S and 0.125 g based on C16H16N4O8S—produced by the Group’s subsidiary, Hebei Guangxiang Pharmaceutical Technology Co., Ltd., were successfully selected. This second-generation cephalosporin antibiotic is primarily indicated for the treatment of infectious diseases caused by susceptible bacteria, with an agreed procurement volume exceeding 1.2 million sachets in the first year. In addition, the Group’s ketotifen fumarate ophthalmic solution 0.025% (0.4 ml: 0.1 mg, calculated on the basis of C₁₉H₁₉NOS) was also selected, providing a new therapeutic option for patients with seasonal allergic conjunctivitis.
The successful winning of bids for multiple product specifications in these two major centralized procurement projects is a testament to the Group’s sustained commitment in recent years to innovation-driven development, robust quality control, and optimized industrial-chain integration. By proactively building end-to-end value-chain advantages spanning active pharmaceutical ingredients, finished dosage forms, and pharmaceutical packaging materials, the Group has significantly enhanced its cost-control capabilities and supply-security assurance, thereby laying a solid foundation for securing wins in centralized procurement.
A spokesperson for the group stated, “Winning this centralized procurement bid is a recognition of our company’s overall strength and will effectively enhance the accessibility of our products. Taking this as an opportunity, we will deepen innovation and R&D, ensure the supply and quality of our pharmaceuticals, better meet clinical needs, benefit patients, and contribute to the Healthy China initiative and the high-quality development of Shijiazhuang’s biopharmaceutical industry.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091